Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VLV010
MIFTS: 44

Vulvovaginitis

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Vulvovaginitis

About this section

MalaCards integrated aliases for Vulvovaginitis:

Name: Vulvovaginitis 12 76 55 44 15 73
Vulvo-Vaginitis 12

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:2273
ICD10 33 N76.0
MeSH 44 D014848
NCIt 50 C35131
SNOMED-CT 68 53277000
UMLS 73 C0042998
Sources

Summaries for Vulvovaginitis

About this section
Disease Ontology : 12 A female reproductive system disease that is characterized by inflammation of the vagina and vulva.

MalaCards based summary : Vulvovaginitis, also known as vulvo-vaginitis, is related to cervicitis and behcet syndrome. An important gene associated with Vulvovaginitis is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Clindamycin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and lung.

Wikipedia : 76 Vaginitis, also known as vulvovaginitis, is inflammation of the vagina and vulva. Symptoms may include... more...

Sources

Related Diseases for Vulvovaginitis

About this section

Diseases related to Vulvovaginitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 216)
# Related Disease Score Top Affiliating Genes
1 cervicitis 30.1 CXCL8 HSPD1
2 behcet syndrome 30.1 CXCL8 HSPD1 IL10
3 allergic rhinitis 30.0 CCL11 CXCL8 IL10
4 viral infectious disease 29.8 CCL5 CXCL8 IL10
5 oral lichen planus 29.6 CCL5 HSPD1
6 peritonitis 29.6 CXCL8 IL10
7 bacterial infectious disease 29.5 IL10 HSPD1 CXCL8
8 chlamydia 29.5 IL10 HSPD1 CXCL8
9 intestinal disease 29.5 CXCL8 IL10
10 human immunodeficiency virus infectious disease 29.5 CCL5 IL10
11 skin disease 29.5 CCL11 CXCL8 IL10
12 rhinitis 29.4 CCL11 CCL5 CXCL8
13 psoriasis 29.3 CCL5 CXCL8 IL10
14 human immunodeficiency virus type 1 29.2 CCL11 CCL5 IL10
15 vulvovaginal candidiasis 12.6
16 vulvovaginal gingival syndrome 12.2
17 vulvovaginal rhabdomyosarcoma 12.2
18 vulvovaginitis, allergic seminal 12.0
19 vaginitis 11.5
20 vulvitis 11.4
21 vulvar vestibulitis syndrome 11.4
22 vulvar disease 11.2
23 candidiasis 11.1
24 lichen planus 10.4
25 bacterial vaginosis 10.4
26 vaginal cancer 10.3
27 candida glabrata 10.2
28 ulceration of vulva 10.2
29 mycobacterium fortuitum 10.2 CXCL8 HSPD1
30 trichomoniasis 10.2
31 papillary conjunctivitis 10.1 CCL11 CXCL8
32 conjunctivitis 10.1 CCL11 CXCL8
33 giant papillary conjunctivitis 10.1 CCL11 CXCL8
34 keratoconjunctivitis 10.1 CCL11 CXCL8
35 pollen allergy 10.1
36 thrombosis 10.1
37 choriocarcinoma 10.1
38 endometrial stromal sarcoma 10.1
39 granuloma inguinale 10.1
40 allergic conjunctivitis 10.1 CCL11 CXCL8
41 carrion's disease 10.1 CCL11 HSPD1
42 tungiasis 10.1 CXCL8 IL10
43 acute transverse myelitis 10.1 CXCL8 IL10
44 transverse myelitis 10.1 CXCL8 IL10
45 pouchitis 10.1 CXCL8 IL10
46 neurosyphilis 10.1 CXCL8 IL10
47 necatoriasis 10.1 CXCL8 IL10
48 trichuriasis 10.1 CXCL8 IL10
49 funisitis 10.1 CXCL8 IL10
50 clonorchiasis 10.1 CXCL8 IL10

Graphical network of the top 20 diseases related to Vulvovaginitis:



Diseases related to Vulvovaginitis
Sources

Symptoms & Phenotypes for Vulvovaginitis

About this section
Sources

Drugs & Therapeutics for Vulvovaginitis

About this section

Drugs for Vulvovaginitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 18323-44-9 29029
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 23593-75-1 2812
4
Fluconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 86386-73-4 3365
5
Dequalinium Approved, Investigational Phase 4 6707-58-0
6
Terconazole Approved Phase 4,Phase 3,Not Applicable 67915-31-5 441383
7 Antibiotics, Antitubercular Phase 4,Not Applicable
8 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Clindamycin palmitate Phase 4,Phase 3,Not Applicable
12 Antitubercular Agents Phase 4
13 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Clindamycin phosphate Phase 4,Phase 3,Not Applicable
18 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Not Applicable
19 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Anti-Infective Agents, Local Phase 4,Phase 3
23
Butoconazole Approved Phase 3,Not Applicable 64872-77-1, 64872-76-0 47472
24
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 5280965 14956
25
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
26
Ketoconazole Approved, Investigational Phase 3 65277-42-1 3823 47576
27 Antiparasitic Agents Phase 3,Phase 2
28 Liposomal amphotericin B Phase 3,Phase 2
29 Antiprotozoal Agents Phase 3,Phase 2
30
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
31 Vaccines Phase 1, Phase 2
32 Gastrointestinal Agents Phase 1, Phase 2
33 Anti-Ulcer Agents Phase 1, Phase 2
34 Antacids Phase 1, Phase 2
35 Immunologic Factors Phase 1, Phase 2
36 Adjuvants, Immunologic Phase 1, Phase 2
37 Pharmaceutical Solutions Phase 2
38 Acidophilus Phase 1,Not Applicable,Early Phase 1
39
Iron Approved Not Applicable 7439-89-6 23925
40
Itraconazole Approved, Investigational Not Applicable 84625-61-6 55283
41
Metronidazole Approved ,Not Applicable 443-48-1 4173
42 Micronutrients Not Applicable
43
Hydroxyitraconazole Not Applicable
44 Trace Elements Not Applicable
45 Bifidobacterium Not Applicable
46 Brewer's Yeast Not Applicable

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Unknown status NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
2 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
3 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
4 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
5 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
6 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
7 Vaginal Infection Study Completed NCT00616330 Phase 3 clindamycin phosphate/butoconazole nitrate;clindamycin phosphate;butoconazole nitrate
8 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
9 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole
10 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
11 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
12 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
13 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
14 Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Recruiting NCT03734991 Phase 3 Ibrexafungerp;Placebo
15 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03562156 Phase 3 VT-1161;Placebo
16 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03561701 Phase 3 VT-1161;Placebo
17 ProF-001_Phase IIa Recruiting NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
18 Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis Not yet recruiting NCT03473418 Phase 3 Ketoconazole;Terconazole
19 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Not yet recruiting NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
20 An Active-Controlled, Dose-Finding Study of SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
21 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
22 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
23 TOL-463 Phase 2 Study for Vaginitis Completed NCT02866227 Phase 2 TOL-463;TOL-463
24 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
25 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Completed NCT02267382 Phase 2 VT-1161;Placebo
26 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
27 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2 VT-1161;Fluconazole
28 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
29 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
30 Patients With Vulvovaginal Candidiasis Recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
31 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Not yet recruiting NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
32 Efficacy Vulvovaginitis Candida Terminated NCT00199264 Phase 2 Albaconazole oral solution
33 Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
34 Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Completed NCT02730494 Phase 1
35 Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection Completed NCT01067131 Phase 1
36 Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy Completed NCT01375439 Not Applicable
37 A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations Completed NCT01039584 Not Applicable Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream
38 Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) Completed NCT00895453 Not Applicable itraconazole;lactobacillus gasseri;classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
39 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis Completed NCT00803738 Not Applicable Terconazole Vaginal Suppository;Terazol Vaginal Suppository
40 Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization Completed NCT02888197
41 Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis Completed NCT02203942
42 Observational Program Neo-Penotran® Forte Completed NCT01335373 Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
43 Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Completed NCT02150655 Early Phase 1
44 Epidemiological Study in Subjects With Vulvovaginal Candidiases Recruiting NCT03064789
45 Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women Recruiting NCT01915251
46 Oral Probiotics for the Treatment and Prevention of Vulvovaginal Infections in Pregnancy - Double-blind, Randomized, Placebo-controlled Study Recruiting NCT02795845 Not Applicable
47 Women's Improvement of Sexual Health (WISH) Demonstration Project Active, not recruiting NCT03045809
48 Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis Not yet recruiting NCT03762083 Not Applicable
49 Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis Not yet recruiting NCT03761628 Not Applicable
50 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Not yet recruiting NCT03075046 Not Applicable

Search NIH Clinical Center for Vulvovaginitis

Cochrane evidence based reviews: vulvovaginitis

Sources

Genetic Tests for Vulvovaginitis

About this section
Sources

Anatomical Context for Vulvovaginitis

About this section

MalaCards organs/tissues related to Vulvovaginitis:

41
Testes, Skin, Lung, Bone, Eye, Prostate, T Cells
Sources

Publications for Vulvovaginitis

About this section

Articles related to Vulvovaginitis:

(show top 50) (show all 389)
# Title Authors Year
1
A nested-PCR strategy for molecular diagnosis of mollicutes in uncultured biological samples from cows with vulvovaginitis. ( 29191491 )
2018
2
Effect of 2-Phenylethanol as Antifungal Agent and Common Antifungals (Amphotericin B, Fluconazole, and Itraconazole) on Candida Species Isolated from Chronic and Recurrent Cases of Candidal Vulvovaginitis. ( 29658789 )
2018
3
Parapoxviral vulvovaginitis in Holstein cows. ( 29429402 )
2018
4
An unusual presentation of pseudocowpox associated with an outbreak of pustular ulcerative vulvovaginitis in a Swedish dairy herd. ( 29153035 )
2018
5
Efficacy, acceptability and tolerability of ZelesseAr for the treatment of non-specific vulvovaginitis in paediatric patients: The NINESSE Study. ( 29877120 )
2018
6
Sexual behaviour and extra-genital colonisation in women treated for recurrent Candida vulvo-vaginitis. ( 29998617 )
2018
7
Prepubertal vulvovaginitis. ( 29970369 )
2018
8
Chronic vulvovaginitis caused by Candida dubliniensis in an immunologically competent adult female. ( 30170531 )
2018
9
First report of Vulvovaginitis due to Cryptococcus magnus in Iran. ( 30186991 )
2018
10
Is multiple-site colonization with Candida spp. related to inadequate response to individualized fluconazole maintenance therapy in women with recurrent Candida vulvovaginitis? ( 30293562 )
2018
11
An Update on the Roles of Non-albicansCandida Species in Vulvovaginitis. ( 30384449 )
2018
12
Candida Vulvovaginitis and Vulvodynia: The Mystery Continues. ( 28836889 )
2017
13
Molecular identification and antifungal susceptibility profile of<i>Candida</i>species isolated from patients with vulvovaginitis in Tehran, Iran. ( 29387119 )
2017
14
Comparison of enzymatic activities in different Candida species isolated from women with vulvovaginitis. ( 28236530 )
2017
15
Evaluation of esterase and hemolysin activities of different <i>Candida</i> species isolated from vulvovaginitis cases in Lorestan Province, Iran. ( 29707672 )
2017
16
Identification of <i>Candida</i> species isolated from vulvovaginitis using matrix assisted laser desorption ionization-time of flight mass spectrometry. ( 29707675 )
2017
17
Cyproterone acetate in the treatment of oestrogen hypersensitivity vulvovaginitis. ( 28718897 )
2017
18
Haemophilus influenzae vulvovaginitis associated with rhinitis caused by the same clone in a prepubertal girl. ( 28621044 )
2017
19
Vulvovaginitis- presentation of more common problems in pediatric and adolescent gynecology. ( 28927766 )
2017
20
Vulvovaginitis: Find the cause to treat it. ( 28322677 )
2017
21
Stratum corneum lipid liposome-encapsulated panomycocin: preparation, characterization, and the determination of antimycotic efficacy against Candida spp. isolated from patients with vulvovaginitis in an in vitro human vaginal epithelium tissue model. ( 28831255 )
2017
22
Characterization and identification of microbial communities in bovine necrotic vulvovaginitis. ( 28093107 )
2017
23
Vulvovaginitis and diabetes. ( 28065975 )
2017
24
Candida vulvovaginitis: A store with a buttery and a show window. ( 27687503 )
2017
25
Clinical Significance and Characteristic Clinical Differences of Cytolytic Vaginosis in Recurrent Vulvovaginitis. ( 27300413 )
2017
26
Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). ( 27393491 )
2016
27
Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis. ( 26991298 )
2016
28
Streptococcus pyogenes as the cause of vulvovaginitis and balanitis in children from Nis, Serbia. ( 27638252 )
2016
29
Personal Hygiene and Vulvovaginitis in Prepubertal Children. ( 26187769 )
2016
30
Phospholipase and proteinase activities of Candida spp. isolates from vulvovaginitis in Iran. ( 27544321 )
2016
31
Recurrent desquamative vulvovaginitis in a young woman. ( 26266812 )
2016
32
Clinical Recommendation: Vulvovaginitis. ( 27969009 )
2016
33
The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model. ( 27796932 )
2016
34
Clinical and microbiologic characteristics of vulvovaginitis in Korean prepubertal girls, 2009-2014: a single center experience. ( 27004204 )
2016
35
Author's reply to comment on: is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). ( 27988816 )
2016
36
Safety, efficacy, and tolerability of differential treatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women. ( 27132409 )
2016
37
Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). ( 28025698 )
2016
38
Clinical presentation, diagnosis and treatment of vulvovaginitis in girls: a current approach and review of the literature. ( 28083751 )
2016
39
Dhatakyadi Varti - An effective local treatment for Upapluta Yonivyapad (vulvovaginitis during pregnancy): A standard controlled randomized clinical trial. ( 29200747 )
2016
40
Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. ( 26001874 )
2015
41
The Role of PCR in the Diagnosis of Candida Vulvovaginitis-a New Gold Standard? ( 26003471 )
2015
42
Theriogenology Question of the Month. Vulvovaginitis or uterine, cervical, or vaginal neoplasia. ( 26642128 )
2015
43
Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center. ( 26083330 )
2015
44
Streptococcal vulvovaginitis in adults: Not a rare entity. ( 26515866 )
2015
45
Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis. ( 25881537 )
2015
46
Guttate Psoriasis Following Streptococcal Vulvovaginitis in a Five-year-old Girl. ( 26024939 )
2015
47
Prevalence of vulvovaginitis and relation to physical findings in girls assessed for suspected child sexual abuse. ( 26294142 )
2015
48
Epidemiology and antifungal susceptibilities of yeasts causing vulvovaginitis in a teaching hospital. ( 25005365 )
2014
49
Microbiological findings of vulvovaginitis in prepubertal girls. ( 24191064 )
2014
50
Recurrent vulvovaginitis. ( 25220102 )
2014
Sources

Variations for Vulvovaginitis

About this section
Sources

Expression for Vulvovaginitis

About this section
Search GEO for disease gene expression data for Vulvovaginitis.
Sources

Pathways for Vulvovaginitis

About this section

Pathways related to Vulvovaginitis according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Akt Signaling 64
Show member pathways
 13.05 CCL11 CCL5 CXCL8 IL10
2
Cytokine Signaling in Immune system 66
Show member pathways
 12.99 CCL11 CCL5 CXCL8 IL10
3
PAK Pathway 64
Show member pathways
 12.93 CCL11 CCL5 CXCL8 IL10
4
Allograft rejection 1 37
Show member pathways
 12.5 CCL11 CXCL8 HSPD1 IL10
5
Immune response CCR3 signaling in eosinophils 22
Show member pathways
 12.01 CCL11 CCL5 CXCL8
6
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.87 CXCL8 HSPD1 IL10
7
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 65
Show member pathways
 11.64 CCL11 CCL5 CXCL8
8
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.64 CCL11 CCL5 CXCL8 IL10
9
Interleukin-4 and 13 signaling 66
11.6 CCL11 CXCL8 IL10
10
Rheumatoid arthritis 37
11.57 CCL5 CXCL8
11
Pertussis 37
11.49 CXCL8 IL10
12
IL4-mediated signaling events 1
11.39 CCL11 IL10
13
Legionellosis 37
11.32 CXCL8 HSPD1
14
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.28 CCL11 CCL5 IL10
15
Malaria 37
11.25 CXCL8 IL10
16
Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway 1
11.22 CCL11 CXCL8
17
Th2 Differentiation Pathway 65
11.2 CCL11 IL10
18
Microglia Activation During Neuroinflammation: Steady-State Microglia 65
11.18 HSPD1 IL10
19
Lung fibrosis 1
11.13 CCL11 CCL5 CXCL8
20
EBV LMP1 signaling 1
10.89 CCL5 CXCL8
21
Interleukin-10 signaling 66
10.82 CCL5 CXCL8 IL10
22
G-protein signaling_Rap2B regulation pathway 22
10.64 CCL11 CCL5 CXCL8 IL10
23
G-protein signaling_RhoB regulation pathway 22
10.15 CCL11 CCL5 CXCL8 IL10
Sources

GO Terms for Vulvovaginitis

About this section

Cellular components related to Vulvovaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.02 CCL11 CCL5 CXCL8 HSPD1 IL10

Biological processes related to Vulvovaginitis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.71 CCL11 CCL5 CXCL8 IL10
2 chemotaxis GO:0006935 9.69 CCL11 CCL5 CXCL8
3 regulation of signaling receptor activity GO:0010469 9.67 CCL11 CCL5 CXCL8 IL10
4 positive regulation of endothelial cell proliferation GO:0001938 9.61 CCL11 IL10
5 cellular response to tumor necrosis factor GO:0071356 9.61 CCL11 CCL5 CXCL8
6 response to glucocorticoid GO:0051384 9.6 HSPD1 IL10
7 monocyte chemotaxis GO:0002548 9.59 CCL11 CCL5
8 response to activity GO:0014823 9.58 HSPD1 IL10
9 lymphocyte chemotaxis GO:0048247 9.58 CCL11 CCL5
10 B cell proliferation GO:0042100 9.57 HSPD1 IL10
11 cellular response to fibroblast growth factor stimulus GO:0044344 9.56 CCL5 CXCL8
12 inflammatory response GO:0006954 9.56 CCL11 CCL5 CXCL8 IL10
13 leukocyte chemotaxis GO:0030595 9.55 CXCL8 IL10
14 eosinophil chemotaxis GO:0048245 9.54 CCL11 CCL5
15 positive regulation of macrophage activation GO:0043032 9.52 HSPD1 IL10
16 neutrophil chemotaxis GO:0030593 9.5 CCL11 CCL5 CXCL8
17 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.49 CCL5 CXCL8
18 response to molecule of bacterial origin GO:0002237 9.48 CXCL8 IL10
19 neutrophil activation GO:0042119 9.46 CCL5 CXCL8
20 cellular response to interleukin-1 GO:0071347 9.33 CCL11 CCL5 CXCL8
21 chemokine-mediated signaling pathway GO:0070098 9.13 CCL11 CCL5 CXCL8
22 cytokine-mediated signaling pathway GO:0019221 8.92 CCL11 CCL5 CXCL8 IL10

Molecular functions related to Vulvovaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.16 CCL11 CCL5
2 chemokine activity GO:0008009 9.13 CCL11 CCL5 CXCL8
3 cytokine activity GO:0005125 8.92 CCL11 CCL5 CXCL8 IL10
Sources

Sources for Vulvovaginitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....